Today: 9 June 2026
AT&T stock jumps as telecoms rally; what to watch before Monday’s open
31 January 2026
1 min read

AT&T stock jumps as telecoms rally; what to watch before Monday’s open

New York, Jan 31, 2026, 16:53 EST — Market closed.

  • AT&T shares climbed 4.3% on Friday, outpacing a weaker overall market.
  • Verizon’s blowout earnings gave the U.S. telecom sector a strong push heading into the weekend.
  • The U.S. jobs report due next week will be the immediate macro test for rate-sensitive, high-yield stocks.

AT&T Inc. shares climbed 4.3% to close at $26.21 on Friday, even as the S&P 500 and Dow each slipped 0.4%. Verizon surged nearly 12%, while T-Mobile added around 4%, pushing the telecom sector into rare outperformance.

After the bell, AT&T slipped to $26.11, shedding 0.4% in after-hours trading and giving back a bit of the day’s advance.

The outperformance is crucial now as telecom is once again viewed as a cash-flow play — a safe spot when growth stocks falter — and Friday’s action thrust the sector back into focus ahead of a week packed with data.

Verizon carried most of the load. The company reported better subscriber growth and detailed cost and capital strategies that propelled its shares to the largest one-day surge since 2008, lifting rival stocks along with it.

Macro data came in mixed. Producer prices increased 0.5% in December, while services prices jumped 0.7%, a stronger-than-expected rise that could keep investors uneasy about future interest rate moves.

AT&T remains buoyed by its recent earnings and guidance. CEO John Stankey noted in a company statement earlier this week, “We achieved or surpassed all of our consolidated full-year guidance for 2025.” AT&T Newsroom

The company also ramped up capital returns. CFO Pascal Desroches announced on the earnings call that “Our Board has authorized an additional $10 billion of share repurchases,” complementing a plan that already calls for about $8 billion in buybacks in 2026. AT&T Investor Relations

Investors find the pitch simple: reliable subscription income, substantial network investments already in the pipeline, and leftover cash — known as “free cash flow,” after covering operating expenses and capital outlays — to fund dividends and share buybacks.

Yet the trade could shift quickly. The partial U.S. government shutdown starting early Saturday might shake markets in the coming week. Telecom remains vulnerable, too—price wars or rising churn might push carriers to boost spending just to hang onto customers.

The key date to watch is the U.S. employment report for January, set for release on Feb. 6. It has the potential to shift rate expectations, impacting dividend-heavy sectors like telecom.

Investors are set to parse the Fed’s latest signals, with minutes from the January meeting dropping on Feb. 18.

AT&T investors head into Monday hoping for a clear sign: was Friday’s telecom rally just a short-lived reaction to Verizon’s results, or the beginning of a wider rotation that can sustain itself as rates and risk appetite evolve?

Stock Market Today

  • Soybean Prices Decline Amid Lower Export Shipments and Reduced Speculative Positions
    June 9, 2026, 9:21 AM EDT. Soybean prices fell between 2 and 5 ½ cents on Monday, with the national average cash price dropping to $10.58 3/4 per bushel. Export shipments for the week ending June 4 decreased by 21.2% from the previous week, totaling 398,186 MT, and are down 28.8% year-over-year. Key buyers included Egypt, China, and Mexico. Marketing year exports stand 20.3% lower compared to last year. Meanwhile, speculative traders reduced their net long positions in soybean futures and options by 33,502 contracts, signaling cautious market sentiment. Soymeal and soy oil futures also declined modestly. A private export sale of 264,000 MT was reported for the 2026/27 season, but overall market pressure weighs on prices going into the week.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Shell share price slips as buyback wraps up; earnings on deck next week
Previous Story

Shell share price slips as buyback wraps up; earnings on deck next week

Renesas stock price: Wolfspeed stake update lands days before Feb. 5 earnings
Next Story

Renesas stock price: Wolfspeed stake update lands days before Feb. 5 earnings

Go toTop